Gelderblom H et al. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;403(10445):2709-19. Abstract

Mastboom MJL et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: An international, retrospective, cohort study. Lancet Oncol 2019;20(6):877-86. Abstract

Mastboom MJL et al. Surgical treatment of localized-type tenosynovial giant cell tumors of large joints: A study based on a multicenter-pooled database of 31 international sarcoma centers. J Bone Joint Surg Am 2019;101(14):1309-18. Abstract

Palmerini E et al. Pexidartinib upfront in a case of tenosynovial giant cell tumor: Proof of concept for a treatment paradigm shift. Oncol Ther 2024;[Online ahead of print]. Abstract

Palmerini E et al. Tenosynovial giant cell tumor observational platform project (TOPP) Registry: A 2-year analysis of patient-reported outcomes and treatment strategies. Oncologist 2023;28(6):e425-35. Abstract

Spierenburg G et al. Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study. Eur J Surg Oncol 2024;50(2):107953. Abstract

Stacchiotti S et al. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts. Canc Treat Rev 2023;112:102491. Abstract

Tap WD et al. Efficacy, safety, and patient-reported outcomes of vimseltinib in patients with tenosynovial giant cell tumor: Results from the phase 3 MOTION trial. ASCO 2024;Abstract 11500.